Once in the clinical arena, results from a small series of low-to-intermediate risk patients with APL suggest the antileukemic advantage of ATRA plus ATO in patients with FLT3-ITD [133,134]. The gene discussed is FLT3; the disease is acute promyelocytic leukemia.